Moderna Inc MRNA shares are trading higher by 3.18% at $165.60 in Friday's pre-market session, recovering some of the losses following the company's first-quarter earnings report.
On Thursday, Moderna reported quarterly earnings of $2.84 per share, which beat the analyst consensus estimate of $2.39. Moderna also reported quarterly sales of $1.90 billion, which missed the analyst consensus estimate of $2.04 billion.
Goldman Sachs analyst Salveen Richter maintains Moderna with a Buy and raises the price target from $206 to $228.
Morgan Stanley maintains Moderna with an Equal-Weight and lowers the price target from $201 to $190.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
